We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+17.99%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$12.1M
(-1.1%)
Cap. Flow
-$142M
Cap. Flow
% of AUM
-13.41%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
262
Reduced
172
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$6.54M |
| 2 |
iShares Gold Trust Micro
IAUM
|
+$4.59M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
+$3.58M |
| 4 |
Intuit
INTU
|
+$3.2M |
| 5 |
T-Mobile US
TMUS
|
+$2.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$17.2M |
| 2 |
Microsoft
MSFT
|
+$10M |
| 3 |
NVIDIA
NVDA
|
+$9.7M |
| 4 |
Amazon
AMZN
|
+$7.99M |
| 5 |
Broadcom
AVGO
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Vericel Corp
VCEL
$2.29B
| $430K | 0.04% |
10,111
+88
| +0.9% | +$3.66K |
|
252
Veracyte
VCYT
$3.59B
| $425K | 0.04% |
15,729
+95
| +0.6% | +$2.75K |
|
253
Diageo
DEO
$52.2B
| $415K | 0.04% |
4,117
| – | – |
|
254
NewAmsterdam Pharma
NAMS
$3.33B
| $408K | 0.04% |
22,549
+521
| +2% | +$9.5K |
|
255
Denali Therapeutics
DNLI
$4.04B
| $408K | 0.04% |
29,178
+50
| +0.2% | +$704 |
|
256
Zai Lab
ZLAB
$2.86B
| $407K | 0.04% |
11,627
-917
| -7% | -$30.1K |
|
257
Recursion Pharmaceuticals
RXRX
$1.76B
| $406K | 0.04% |
80,269
+1,024
| +1% | +$5.03K |
|
258
Deckers Outdoor
DECK
$12.4B
| $403K | 0.04% |
3,908
| – | – |
|
259
NovoCure
NVCR
$2.05B
| $399K | 0.04% |
22,391
+344
| +2% | +$5.99K |
|
260
CG Oncology
CGON
$6.82B
| $398K | 0.04% |
15,310
+40
| +0.3% | +$964 |
|
|
GRAL
261
GRAIL Inc
GRAL
$3.08B
| $397K | 0.04% |
7,725
+985
| +15% | +$35.7K |
|
262
Agios Pharmaceuticals
AGIO
$2.04B
| $387K | 0.04% |
11,632
+139
| +1% | +$4.21K |
|
263
Genmab
GMAB
$19.6B
| $381K | 0.04% |
18,421
-27,781
| -60% | -$570K |
|
264
BioCryst Pharmaceuticals
BCRX
$2.71B
| $377K | 0.04% |
42,027
+113
| +0.3% | +$1.05K |
|
265
AutoZone
AZO
$49.7B
| $371K | 0.03% |
100
| – | – |
|
266
IDEAYA Biosciences
IDYA
$3.56B
| $370K | 0.03% |
17,590
+32
| +0.2% | +$614 |
|
267
Indivior Pharmaceuticals
INDV
$4.57B
| $369K | 0.03% |
25,059
+159
| +0.6% | +$1.85K |
|
268
Disc Medicine
IRON
$3.09B
| $368K | 0.03% |
6,956
+22
| +0.3% | +$1.03K |
|
269
Harmony Biosciences
HRMY
$2.32B
| $364K | 0.03% |
11,533
+30
| +0.3% | +$965 |
|
270
Adaptive Biotechnologies
ADPT
$4.02B
| $355K | 0.03% |
30,512
+910
| +3% | +$8.27K |
|
|
FOLD
271
DELISTED
Amicus Therapeutics
FOLD
| $354K | 0.03% |
61,847
+220
| +0.4% | +$1.42K |
|
272
Huazhu Hotels Group
HTHT
$12.7B
| $346K | 0.03% |
10,200
| – | – |
|
273
ARS Pharmaceuticals
SPRY
$601M
| $344K | 0.03% |
19,726
+232
| +1% | +$3.35K |
|
274
Beam Therapeutics
BEAM
$2.76B
| $344K | 0.03% |
20,197
+3,175
| +19% | +$55.3K |
|
275
Tarsus Pharmaceuticals
TARS
$3.07B
| $342K | 0.03% |
8,438
+740
| +10% | +$33.3K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2025 Portfolio in Review
As of Q2 2025, China Universal Asset Management Company held 501 positions worth $1.06B, down 1.1% from $1.07B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
China Universal Asset Management Company withdrew a net $142M in Q2 2025, closing 24 positions and reducing 172 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $2.81M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 37% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, China Universal Asset Management Company opened a new position in Tencent Music worth $1.66M.
- China Universal Asset Management Company's largest Q2 2025 buy was Tencent Music: 85,000 shares worth $1.66M.
- China Universal Asset Management Company added most to SPDR Gold Trust in Q2 2025, an estimated $6.54M increase.
- China Universal Asset Management Company's biggest Q2 2025 reduction was Apple, cutting an estimated $17.2M.
- China Universal Asset Management Company fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $2.81M.
- China Universal Asset Management Company's ten largest holdings make up 38% of its $1.06B portfolio in Q2 2025.
- China Universal Asset Management Company opened 15 new positions and closed 24 in Q2 2025.
- China Universal Asset Management Company's portfolio value fell 1.1% quarter-over-quarter to $1.06B.
Based on China Universal Asset Management Company's 13F filing for Q2 2025, filed 28 Aug 2025.